Published in final edited form as:

Chemistry. 2012 January 23; 18(4): 1194–1201. doi:10.1002/chem.201102545.

Total Synthesis of a Glycosylphosphatidylinositol Anchor of the Human Lymphocyte CD52 Antigen

Dr. Srinivas Burgula[†], Dr. Benjamin M. Swarts[†], and Prof. Dr. Zhongwu Guo

Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202 (USA),
Phone: (+1) 313 577 2557, Fax: (+1) 313 577 8822

Zhongwu Guo: zwguo@chem.wayne.edu

Abstract

The first total synthesis of a glycosylphosphatidylinositol (GPI) anchor bearing a polyunsaturated arachidonoyl fatty acid is reported. This lipid is found in mammalian GPIs that do not undergo lipid remodeling, a process that has important implications in the localization and function of GPI-anchored proteins. Incorporation of this oxidation- and reduction-sensitive lipid in the target GPI was accomplished using the *para*-methoxybenzyl (PMB) group for permanent hydroxyl group protection, which featured a selective, rapid, and efficient global deprotection protocol. The flexibility of this synthetic strategy was further highlighted by the inclusion of two additional GPI core structural modifications present in the GPI anchor of the human lymphocyte CD52 antigen.

Keywords

carbohydrate; GPI anchor; CD52 antigen; lipid remodeling; *para*-methoxybenzyl; arachidonoyl

Introduction

Numerous eukaryotic cell surface proteins are anchored to the plasma membrane by glycosylphosphatidylinositols (GPIs), a family of glycolipids that are posttranslationally attached to proteins at their C-termini.^[1] GPI-anchored proteins (GPI-APs) play important roles in many biological and pathological events, such as cell recognition and adhesion,^[2] signal transduction,^[3] host defense,^[1c, 4] and acting as receptors for viruses and toxins.^[4] In the 1980s, Ferguson and coworkers elucidated the GPI anchor core structure conserved among all species: H₂NEt-(PO₄)-6-Man α (1→2)Man α (1→6)Man α (1→4)GlcNH₂ α (1→6)*myo*-inositol-1-(PO₄)-glycerolipid.^[5] Modifications of the core structure are frequent and primarily include additional glycans and phosphoethanolamine groups linked to Man residues, while the phosphatidylinositol (PI) fatty acids may differ in chain length and unsaturation.^[1c, 1d]

The structural diversity of GPI lipids is generated by the “lipid remodeling” process of GPI-APs.^[6] GPI biosynthesis begins from cellular PI, which typically contains a polyunsaturated arachidonoyl lipid (20:4) at the sn-2 position. The arachidonoyl group can be replaced by other lipids through a series of transformations in the Golgi apparatus, and as a result most mature mammalian GPI-APs contain only saturated fatty acids. However, several mature GPI-APs bearing 2-arachidonoyl PI have been identified, including a major form of the

Correspondence to: Zhongwu Guo, zwguo@chem.wayne.edu.

[†]These authors contributed equally to this work.

Supporting information for this article is available on the WWW under <http://www.chemurj.org/> or from the author.

human lymphocyte CD52 antigen.^[7] The effects of unremodeled lipids on the function of lymphocyte CD52 and other GPI-APs have not been thoroughly explored, though in general it is believed that the structure of GPI lipids has important implications in the localization and function of GPI-APs. For example, a recent study demonstrated that saturated fatty acids resulting from lipid remodeling are required for association of mammalian GPI-APs with lipid rafts.^[8] On the other hand, unsaturated lipids found in GPIs from the protozoan parasite *Trypanosoma cruzi* are thought to be responsible for potent proinflammatory activity.^[9]

The CD52 antigen is a GPI-anchored glycopeptide expressed by human lymphocyte and sperm cells.^[7b, 10] Although lymphocyte and sperm CD52 share an identical dodecapeptide sequence, structural variations in their *N*-glycan and GPI anchor lead to distinct biological activities.^[11] Whereas lymphocyte CD52 is a target for monoclonal antibody-based therapy of immune system related diseases such as leukaemia,^[12] antibodies specific to sperm CD52 have been identified in infertile women, suggesting potential for immunocontraceptive development.^[13] Intriguingly, there are two major forms of lymphocyte CD52, which exhibit two extremes of GPI lipid remodeling, one carrying exclusively distearoyl-PI and the other carrying inositol-palmitoylated stearyl-arachidonoyl PI.^[7b] Evaluating the consequences of lipid structural variations on GPI-AP trafficking, surface localization, and antibody binding can be aided by chemical synthesis, which is an invaluable approach to obtaining structurally defined GPI anchors for biological study.^[14]

To develop a strategy for accessing GPIs relevant to studying the effects of lipid remodeling and to continue our synthetic studies of GPI anchors^[15] and the human CD52 antigen,^[16] we targeted lymphocyte CD52 GPI anchor **1** for total synthesis. The target molecule contained modifications of the GPI core glycan present in lymphocyte CD52, including additional phosphoethanolamine and mannose groups linked to the 2-*O*-positions of Man-I and Man-III, respectively. Most importantly, compound **1** contained a stearyl-arachidonoyl PI moiety, which is present in lymphocyte CD52 and other GPI-APs that do not undergo lipid remodeling. To achieve the synthetically challenging incorporation of a polyunsaturated arachidonoyl lipid in GPI **1**, we employed a strategy based on *para*-methoxybenzyl (PMB) hydroxyl protection, which was recently developed in our laboratory to enable the synthesis of GPIs carrying sensitive functionalities that are not compatible with traditional carbohydrate protection chemistries.^[15d, 15e]

Results and Discussion

A convergent approach was used for the construction of GPI **1** that relied on a key glycosylation between PMB-protected coupling partners pseudodisaccharide acceptor **2** and tetramannosyl donor **3** (Scheme 1). Silyl ether protecting groups at the Man-I 2-*O*- and Man-III 6-*O*-positions would be selectively removed at a late stage to enable double phosphorylation of the sites with phosphoramidite **4**. Acceptor **2** could be accessed through phospholipidation of **5** with phosphoramidite **6**, which would attach the arachidonoyl-containing glycerolipid. Glycosyl donor **3** would arise from sequential α -mannosylations of disaccharide **7**. Guided by previous success, we used the Schmidt method^[17] to stereoselectively couple all PMB-protected glycosylation partners.

The preparation of pseudodisaccharide **2** is shown in Scheme 2. 2-Arachidonoyl glycerides are known to be sensitive to (1) heat, base, and acid, which promote rearrangement to the more stable 1-arachidonoyl isomer and (2) air and light, which result in oxidation of the lipid alkenes.^[18] Care was taken in the synthesis to minimize exposure to these conditions. The preparation of phosphoramidite **6** commenced with stearylation of optically pure glycerol derivative **10**, which was carried out with EDCI and DMAP (70%). After acid-

catalyzed acetonide hydrolysis, the resulting diol **11** was treated with TBSCl and imidazole to selectively protect its primary hydroxyl group. Next, with rigorous exclusion of air, light, and moisture, the secondary alcohol was esterified with arachidonic acid in the presence of EDCI and DMAP. The reaction proceeded in 99% yield, and NMR spectroscopic analysis of the product confirmed that the polyunsaturated lipid chain was intact. Previous reports describing arachidonoyl migration during deprotection of the adjacent hydroxyl group^[18] were echoed in our work, as desilylation using TBAF/AcOH was accompanied by unwanted transesterification. Fortunately, triethylamine trihydrofluoride proved mild enough to effect migration-free removal of the TBS group, giving stearoyl-arachidonoyl glyceride **12** in 98% yield. Compound **12** was converted to its corresponding phospholipid precursor **6** by coupling with commercially available 2-cyanoethyl *N,N,N',N'*-tetraisopropyl phosphoramidite in 88% yield.

Phospholipidation of the PMB-protected pseudodisaccharide **5**^[15d] was realized by reaction with freshly prepared phosphoramidite **6** in the presence of 1*H*-tetrazole. Chemoselective oxidation of the resulting intermediate phosphite to phosphate **13** with *t*-BuOOH was performed *in situ* at -40 °C without affecting the sensitive lipid alkenes. After partial purification on silica gel, compound **13** was treated with triethylamine trihydrofluoride to remove the sterically hindered glucosamine 4-*O*-TBS group to afford pseudodisaccharide **2** in 55% yield over two steps. At this stage, the ~1:1 diastereomeric mixture was separated by semi-preparative HPLC in order to simplify characterization of downstream GPI intermediates. At each step in the synthesis of **2**, the structural integrity of the arachidonoyl lipid was confirmed by NMR spectroscopy and mass spectrometry.

With pseudodisaccharide **2** in hand, we turned our attention to the synthesis of tetramannosyl donor **3**. Previously, we synthesized PMB-protected dimannose thioglycoside **7**,^[15d] which possessed the appropriate features to access **3** en route to the synthetic target **1**: (1) orthogonal protection at the Man-I 2-*O*-position to enable later phosphorylation; (2) anomeric thioether for facile conversion to a trichloroacetimidate glycosyl donor; (3) free Man-II 2-*O*-position for extension of the glycan chain. For the latter purpose, PMB-protected mannosyl donors **8** and **9** were prepared from mannose pentaacetate **14** (Scheme 3). To obtain Man-III donor **8**, known orthoester **15**^[19] was first converted to **16** by sequential deacetylation with NaOMe/MeOH, 6-*O*-silylation with TBDPSCl/imidazole (68% over two steps), and *para*-methoxybenzylation of the 3-*O*- and 4-*O*-positions (71%). After acid-catalyzed regioselective opening of the orthoester ring (78%), the resulting hemiacetal was converted to trichloroacetimidate **8** by Cl₃CCN and DBU. Man-IV donor **9** was prepared from allyl glycoside **17**. Replacement of the acetates by PMB groups gave **18** (85% over two steps), which underwent palladium-catalyzed anomeric deallylation followed by treatment with Cl₃CCN and DBU to give trichloroacetimidate **9**.

Assembly of the tetramannose fragment from building blocks **7–9** is depicted in Scheme 4. Coupling of dimannose alcohol **7** and Man-III donor **8** was performed under standard Schmidt conditions, i. e. catalytic TMSOTf and MS 4 Å in CH₂Cl₂ at 0 °C. Trimannose **19** was produced in 72% yield with complete α stereoselectivity imparted by neighboring group participation from the donor 2-*O*-acetyl group, which was subsequently removed using NaOMe in MeOH to afford **20** in 97% yield. To install the Man-IV unit, we pursued a route initiated by glycosylation of **20** with known mannosyl trichloroacetimidate **21**,^[15d] which carried a temporary stereodirecting acetyl group at its 2-*O*-position that would be converted to a PMB group following α-stereoselective glycosylation (Scheme 4A). Coupling of **20** and **21** under standard Schmidt conditions furnished the desired tetramannoside in a moderate 44% yield with excellent stereoselectivity. However, subsequent attempts to replace the Man IV 2-*O*-acetate with a PMB group failed due to base-promoted cleavage of the TBDPS group. To circumvent this problem and improve reactivity by using an armed glycosyl

donor,^[20] trimannose **20** was instead coupled with fully PMB-protected donor **9** using Schmidt conditions to directly give **22** in an increased yield (Scheme 4B). However, the stereoselectivity of this reaction was low ($\alpha:\beta = 3:2$), which was in contrast to previous results obtained in a nearly identical system in which acceptor **7** was glycosylated by a similar 2-*O*-PMB-protected mannosyl donor with complete α -stereoselectivity.^[15d]

The α - and β -anomers of **22** were inseparable by HPLC on large-scale, so we explored conditions for removal of the Man-I 2-*O*-allyl group for two purposes, namely improving anomer separation and avoiding late-stage deallylation, as the latter is incompatible with the arachidonoyl lipid. Cha's titanium(IV)-mediated deallylation^[21] was efficient for this purpose (78% over two steps), whereas other methods were low-yielding. After anomer separation by semi-preparative HPLC, the free hydroxyl group of **23** was protected with a TES group (76%) to differentiate the Man-I 2-*O*- and Man-III 6-*O*-positions for later double phosphorylation. After pseudodisaccharide **2** and tetramannose thioglycoside **24** were obtained, they were used to construct the target GPI as shown in Scheme 5. Direct glycosylation of **2** using thioglycoside **24** was inefficient, so **24** was converted to trichloroacetimidate **3** via NIS-promoted hydrolysis of the anomeric thioether (92%) followed by treatment of the intermediate hemiacetal **25** with Cl_3CCN and DBU (99%). The key glycosylation between **3** and pseudodisaccharide **2** under Schmidt conditions gave the desired pseudohexasaccharide, which, after workup but without purification, was directly treated with triethylamine trihydrofluoride to effect desilylation of the ManI 2-*O*-TES and Man-III 6-*O*-TBS groups. Although the resulting diol **26** was isolated in a moderate yield (39% over two steps), the stereoselectivity of the glycosylation step was excellent (only the α -isomer was observed). Compound **26** was fully characterized, and the stereochemistry of each mannosidic bond was established as α using ^{13}C NMR J_{CH} coupling constants: δ 101.9 ($J_{\text{CH}} = 179.7$ Hz, Man-III), 100.5 ($J_{\text{CH}} = 173.4$ Hz, Man-I), 99.3 ($J_{\text{CH}} = 178.1$ Hz, Man-IV), 99.2 ($J_{\text{CH}} = 178.1$ Hz, Man-II).^[22]

To install both phosphoethanolamine units simultaneously, diol **26** was doubly phosphorylated using phosphoramidite **4** in the presence of 1*H*-tetrazole followed by chemoselective oxidation with *t*-BuOOH at -40 °C. The reaction proceeded in 37% yield to afford **27**, which existed as an inconsequential mixture of diastereomers originating at the newly formed stereogenic phosphates. A monophosphorylated product was also obtained in 15% yield. Finally, compound **27** was globally deprotected in under 3 hours using a three-step, one-pot procedure involving zinc-mediated reduction of GlcN_3 to GlcNH_2 , DBU-promoted cleavage of the cyanoethoxyl and Fmoc groups, and TFA treatment to remove all PMB groups. Following purification using Sephadex-LH20 size exclusion chromatography, GPI **1** was obtained in 90% yield over the final three steps. The structure and homogeneity of the target compound were confirmed using $^1\text{H}/^{31}\text{P}$ and 2D NMR spectroscopy and MALDI mass spectrometry.

Conclusion

The construction of lymphocyte CD52 GPI anchor **1** represents the first total synthesis of a GPI anchor bearing unremodeled PI fatty acids, namely a polyunsaturated arachidonoyl lipid at the sn-2 position. GPI **1** and related compounds are useful for studying the impact of lipid structures on the functions of GPIs and GPI-APs. Inclusion of the oxidation- and reduction-sensitive arachidonoyl lipid was made possible by utilizing global PMB protection, which featured a very mild and rapid three-step, one-pot deprotection protocol. Furthermore, two additional GPI core structural modifications present in lymphocyte CD52, specifically additional phosphoethanolamine and mannose units, were incorporated in the target molecule, which further demonstrated the applicability of the PMB protection strategy to the efficient synthesis of highly complex and sensitively functionalized GPI anchors.

Experimental Section

This section contains experimental procedures as well as MS and NMR data for selected key intermediates and the target compound. For all other procedures and characterization data, refer to the supporting information.

6-*O*-[2-Azido-2-deoxy-3,6-di-*O*-(*p*-methoxybenzyl)- α -D-glucopyranosyl]-1-*O*-[(2-cyanoethoxy)-(2-*O*-arachidonoyl-3-*O*-stearoyl-*sn*-glycerol)-phosphono]-2,3,4,5-tetra-*O*-(*p*-methoxybenzyl)-myo-inositol (**2**)

To a stirring solution of **5** (40 mg, 0.030 mmol) and 1*H*-tetrazole (0.45 M solution in acetonitrile, 0.44 mL, 0.20 mmol) in anhydrous CH₂Cl₂-CH₃CN (3:1, 6 mL) in the dark under Ar at rt was slowly added a solution of freshly prepared phosphoramidite **6** (84 mg in 1.0 mL dry CH₂Cl₂, 0.10 mmol). After stirring the reaction mixture at rt under Ar for 1 h, it was cooled to -40 °C and treated with *tert*-butyl hydroperoxide (5.5 M solution in decane, 60 μ L, 0.33 mmol). The solution was further stirred for 3 h at -20 °C, then Me₂S (49 μ L, 0.66 mmol) was added and stirring continued for an additional 1 h at -20 °C. The mixture was poured into saturated aqueous NaHCO₃ and extracted three times with CH₂Cl₂. The combined organic layer was dried over Na₂SO₄ and concentrated under vacuum. Purification by silica gel column chromatography gave the desired intermediate **13** (briefly characterized by MALDI-MS), which was then dissolved in anhydrous THF-CH₃CN (1:1, 2.5 mL) and treated with Et₃N·3HF (0.5 mL) under Ar at rt. After stirring for 13 days at rt, the reaction was quenched by dropwise addition of saturated aqueous NaHCO₃. The mixture was extracted three times with CH₂Cl₂, and the combined organic layer was dried over Na₂SO₄, concentrated in vacuum, and purified by silica gel column chromatography (hexanes-acetone 2:1) to afford compound **2** (34 mg, 55% over two steps) as a ~1:1 diastereomeric mixture originating at phosphorus atom. Preparative HPLC (Waters Nova-Pak Silica 6 μ m, 300 $\times$ 19 mm, eluent 30% acetone in hexane, 10 mL/min, isomer **2a** *t*_R = 13.4 min, isomer **2b** *t*_R = 13.9 min) was used to separate the mixture. Characterization data for **2a**: ¹H NMR (CDCl₃, 500 MHz): δ 7.35 (d, *J* = 8.5 Hz, 2 H), 7.32 (d, *J* = 8.5 Hz, 2 H), 7.28 (d, *J* = 8.5 Hz, 2 H), 7.21 (d, *J* = 8.5 Hz, 2 H), 7.16-7.12 (m, 4 H), 6.90-6.86 (m, 6 H), 6.84 (dd, *J* = 8.5, 1.8 Hz, 2 H), 6.79 (dd, *J* = 8.5, 1.8 Hz, 2 H), 6.77 (dd, *J* = 8.8, 1.8 Hz, 2 H), 5.43-5.32 (m, 8 H), 5.39 (d, *J* = 3.7 Hz, 1H, 1-position), 5.25-5.20 (m, 1 H), 4.94 (d, *J* = 10.7 Hz, 1 H), 4.92 (d, *J* = 10.7 Hz, 1 H), 4.86 (d, *J* = 10.4 Hz, 1 H), 4.81 (d, *J* = 11.0 Hz, 1 H), 4.79 (d, *J* = 10.7 Hz, 1 H), 4.69 (d, *J* = 10.4 Hz, 1 H), 4.68 (d, *J* = 11.3 Hz, 1 H), 4.67 (d, *J* = 11.0 Hz, 1 H), 4.63-4.59 (m, 2 H), 4.42-4.40 (m, 2 H), 4.37 (d, *J* = 11.6 Hz, 1 H), 4.36-4.32 (m, 2 H), 4.29-4.21 (m, 4 H), 4.16-4.12 (m, 1 H), 4.12-4.08 (m, 1 H), 4.04-4.00 (m, 2 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.77-3.76 (m, 1 H), 3.75 (s, 3 H), 3.70-3.65 (m, 2 H), 3.51 (dd, *J* = 9.8, 1.5 Hz, 1 H), 3.40 (t, *J* = 9.5 Hz, 1 H), 3.29 (ddd, *J* = 14.6, 10.7, 4.0 Hz, 2 H), 3.17 (dd, *J* = 10.4, 3.7 Hz, 1 H), 2.85-2.76 (m, 6 H), 2.33-2.27 (m, 4 H), 2.10-2.03 (m, 6 H), 1.71-1.64 (m, 2 H), 1.61-1.55 (m, 2 H), 1.39-1.34 (m, 4 H), 1.33-1.20 (m, 30 H), 0.91-0.84 (m, 6 H). ¹³C NMR (CDCl₃, 125 MHz): δ 173.2, 172.6, 159.4, 159.2, 159.15, 159.10, 159.08, 159.03, 130.8, 130.7, 130.5, 130.3, 130.25, 130.23, 130.0, 129.8, 129.5, 129.29, 129.26, 129.04, 128.96, 128.7, 128.6, 128.3, 128.1, 127.8, 127.5, 116.4, 114.0, 113.8, 113.7, 113.65, 113.63, 97.5, 81.2, 80.6, 80.3, 78.3, 76.4, 75.5, 75.3, 74.9, 74.4, 73.0, 72.5, 72.1, 69.7, 69.4, 68.7, 66.0, 62.43, 62.40, 62.3, 61.4, 55.26, 55.25, 55.23, 33.9, 33.5, 31.9, 31.5, 29.72, 29.71, 29.67, 29.5, 29.4, 29.3, 29.1, 27.2, 26.4, 25.63, 25.60, 24.8, 24.7, 22.7, 22.6, 19.7, 19.6, 14.14, 14.09. ³¹P NMR (CDCl₃, 160 MHz): δ -1.40. [α]_D²⁵ = +32.0° (*c* 0.5, CHCl₃). HRMS (ESI): calcd. for C₁₀₄H₁₄₃N₄NaO₂₃P [M+Na]⁺ *m/z*, 1869.9778; found, 1869.9824. Isomer **2a** was carried forward to complete the synthesis.

Phenyl [2,3,4,6-tetra-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[6-*O*-(*tert*-butyldiphenylsilyl)-3,4-di-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[3,4,6-tri-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 6)-2-*O*-allyl-3,4-di-*O*-(*p*-methoxybenzyl)-1-thio- α -D-mannopyranoside (22**)**

A mixture of trichloroacetimidate donor **9** (600 mg, 0.74 mmol), trimannose acceptor **20** (850 mg, 0.49 mmol), and MS 4 Å (300 mg) in anhydrous CH₂Cl₂ (10 mL) was stirred under an Ar atmosphere at rt for 1 h. The reaction mixture was cooled to 0 °C, then TMSOTf (13 μ L, 0.07 mmol) was added and the reaction stirred for 10 min. Neutralization with triethylamine was followed by filtration through a celite pad to remove MS 4 Å and then concentration under vacuum. The residue was purified by silica gel column chromatography (toluene-EtOAc 10:1) to give an inseparable mixture of α,β -anomers **22**. At this point the isolated yield could not be obtained due to the presence of an inseparable impurity, but a small amount of mixture **22** was subjected to semi-preparative HPLC to get α,β -anomers for characterization (Waters Nova-Pak Silica 6 μ m, 300 $\times$ 19 mm, eluent 33% acetone in hexanes, 10 mL/min, **22a** t_R = 23.35 min, **22b** t_R = 24.00 min, partially overlapping peaks). Characterization data (listed below for each anomer of **22**) was obtained, but the poor separation made purification by semi-preparative HPLC on a larger scale impossible, so we opted to purify after the next step (deallylation) to get the isolated yield for the glycosylation-deallylation two-step sequence. Characterization data for **22a**: ¹H NMR (CDCl₃, 500 MHz, α -isomer): δ 7.71 (d, J = 6.7 Hz, 2 H), 7.67 (dd, J = 7.3, 1.8 Hz, 2 H), 7.38 (d, J = 7.6 Hz, 2 H), 7.33-7.26 (m, 10 H), 7.25-7.20 (m, 6 H), 7.18-7.13 (m, 6 H), 7.11-6.99 (m, 9 H), 6.89 (d, J = 8.5 Hz, 2 H), 6.82-6.75 (m, 12 H), 6.74-6.72 (m, 6 H), 6.70-6.67 (m, 2 H), 5.87-5.79 (m, 1 H), 5.44 (d, J = 1.2 Hz, 1 H, Man-I 1-position), 5.37 (d, J = 1.5 Hz, 1 H, Man-III 1-position), 5.30 (d, J = 1.2 Hz, 1 H, Man-IV 1-position), 5.24 (dd, J = 17.1, 1.2 Hz, 1 H), 5.12 (dd, J = 10.4, 1.2 Hz, 1 H), 4.82 (d, J = 1.2 Hz, 1 H, Man-II 1-position), 4.81 (d, J = 10.4 Hz, 1 H), 4.78 (d, J = 10.4 Hz, 1 H), 4.78 (d, J = 10.4 Hz, 1 H), 4.75 (d, J = 11.0 Hz, 1 H), 4.64-4.56 (m, 5 H), 4.53 (d, J = 10.7 Hz, 1 H), 4.51-4.48 (m, 2 H), 4.47 (d, J = 11.0 Hz, 1 H), 4.42 (d, J = 10.4 Hz, 1 H), 4.39 (d, J = 11.9 Hz, 1 H), 4.38 (d, J = 10.1 Hz, 1 H), 4.37 (d, J = 10.4 Hz, 1 H), 4.37-4.31 (m, 4 H), 4.27-4.25 (m, 2 H), 4.16-4.13 (m, 2 H), 4.09-4.05 (m, 1 H), 4.04-3.98 (m, 2 H), 3.96-3.92 (m, 3 H), 3.90-3.86 (m, 5 H), 3.85-3.83 (m, 2 H), 3.83 (s, 3 H), 3.83-3.80 (m, 2 H), 3.80 (s, 3 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.73 (s, 3 H), 3.72 (s, 3 H), 3.72 (s, 3 H), 3.71 (s, 3 H), 3.71-3.70 (m, 2 H), 3.70 (s, 3 H), 3.68-3.64 (m, 2 H), 3.66 (s, 3 H), 3.60-3.56 (m, 2 H), 3.56 (s, 3 H), 3.54-3.50 (m, 2 H), 0.99 (s, 9 H). ¹³C NMR (CDCl₃, 125 MHz, α -isomer): δ 159.5, 159.4, 159.35, 159.30, 159.2, 159.10, 159.08, 136.1, 135.9, 135.2, 134.9, 134.0, 133.4, 131.5, 131.2, 131.1, 130.9, 130.85, 130.77, 130.7, 130.6, 130.5, 130.4, 130.0, 129.9, 129.8, 129.65, 129.56, 129.5, 129.4, 129.2, 127.93, 127.89, 127.2, 118.0, 114.1, 114.0, 113.94, 113.88, 113.8, 113.74, 113.71, 100.2 (Man-III), 99.5 (Man-IV), 99.4 (Man-II), 86.1 (Man-I), 80.4, 80.1, 79.6, 76.6, 75.0, 74.9, 74.8, 74.7, 74.6, 74.5, 74.4, 74.2, 73.6, 73.2, 72.9, 72.5, 72.4, 72.1, 71.9, 71.7, 71.6, 71.2, 69.0, 68.6, 66.7, 66.0, 63.4, 55.52, 55.48, 55.46, 55.4, 55.34, 55.31, 55.2, 27.1, 19.5. ¹³C NMR J_{CH} values (125 MHz): 100.2 (J_{CH} = 176.0 Hz, Man-III), 99.5 (J_{CH} = 176.0 Hz, Man-IV), 99.4 (J_{CH} = 174.0 Hz, Man-II), 86.1 (J_{CH} = 169.0 Hz, Man-I). HRMS (ESI): calcd. for C₁₃₇H₁₅₆NaO₃₁SSi [M+Na]⁺ m/z , 2380.0018; found, 2380.0103. Characterization data for **22b**: ¹H-NMR (CDCl₃, 500 MHz, β -isomer): δ 7.70 (d, J = 6.7 Hz, 2 H), 7.64 (d, J = 6.7 Hz, 2 H), 7.41 (d, J = 7.3 Hz, 2 H), 7.38-7.33 (m, 2 H), 7.33-7.29 (m, 8 H), 7.26-7.23 (m, 6 H), 7.22-7.16 (m, 4 H), 7.14-7.07 (m, 8 H), 7.05-7.00 (m, 2 H), 6.97 (d, J = 8.5 Hz, 2 H), 6.88 (d, J = 8.5 Hz, 2 H), 6.85 (d, J = 8.8 Hz, 2 H), 6.82-6.71 (m, 11 H), 6.69-6.67 (m, 4 H), 6.59 (d, J = 8.5 Hz, 2 H), 5.89-5.80 (m, 1 H), 5.47 (d, J = 1.2 Hz, 1 H, Man-I 1-position), 5.41 (d, J = 1.5 Hz, 1 H, Man-III 1-position), 5.25 (dd, J = 17.1, 1.5 Hz, 1 H), 5.13 (dd, J = 10.4, 1.2 Hz, 1 H), 4.96 (d, J = 11.0 Hz, 1 H), 4.84 (d, J = 1.2 Hz, 1 H, Man-II 1-position), 4.82 (d, J = 1.2 Hz, 1 H, Man-IV 1-position), 4.81 (d, J = 10.1 Hz, 1 H), 4.80 (d, J = 10.4 Hz, 1 H), 4.75 (d, J = 10.4 Hz, 1 H), 4.71 (d, J = 11.0 Hz, 1 H), 4.62-4.58

(m, 4 H), 4.56-4.52 (m, 1 H), 4.50-4.46 (m, 4 H), 4.44-4.33 (m, 7 H), 4.31-4.23 (m, 3 H), 4.19 (dd, $J = 9.5, 4.6$ Hz, 1 H), 4.13-4.09 (m, 1 H), 4.08-3.99 (m, 3 H), 3.94-3.86 (m, 7 H), 3.84-3.82 (m, 2 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.80 (s, 3 H), 3.78 (s, 3 H), 3.80-3.78 (m, 2 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.73-3.71 (m, 1 H), 3.70 (s, 3 H), 3.70 (s, 3 H), 3.68-3.66 (m, 1 H), 3.65 (s, 3 H), 3.65 (s, 3 H), 3.60-3.52 (m, 4 H), 3.50 (s, 3 H), 3.25 (dd, $J = 9.2, 2.7$ Hz, 1 H), 3.13 (dd, $J = 9.2, 2.7$ Hz, 1 H), 0.99 (s, 9 H). ^{13}C NMR (CDCl_3 , 125 MHz, β -isomer): δ 159.5, 159.4, 159.28, 159.27, 159.24, 159.22, 159.18, 159.1, 159.0, 136.1, 135.8, 135.3, 134.9, 134.1, 133.6, 131.5, 131.4, 131.3, 131.12, 131.09, 131.0, 130.9, 130.8, 130.72, 130.68, 130.5, 130.4, 130.3, 130.2, 129.88, 129.86, 129.83, 129.81, 129.78, 129.73, 129.66, 129.63, 129.56, 129.5, 129.4, 129.3, 127.84, 127.82, 127.2, 118.0, 114.2, 114.1, 113.9, 113.82, 113.79, 113.78, 113.7, 113.6, 113.5, 99.4 (Man-II), 99.2 (Man-III), 86.0 (Man-I), 82.2 (Man-IV), 80.6, 80.3, 78.0, 77.5, 76.6, 76.0, 75.1, 74.91, 74.87, 74.8, 74.7, 74.6, 74.5, 74.3, 74.2, 73.8, 73.4, 73.2, 73.0, 72.4, 72.1, 71.6, 70.8, 70.1, 69.5, 69.0, 66.7, 63.8, 55.52, 55.47, 55.4, 55.34, 55.31, 55.29, 55.21, 55.17, 27.0, 19.5. ^{13}C NMR J_{CH} values (125 MHz): 99.4 ($J_{\text{CH}} = 163.0$ Hz, Man-II), 99.2 ($J_{\text{CH}} = 164.0$ Hz, Man-III), 86.0 ($J_{\text{CH}} = 168.0$ Hz, Man-I), 82.2 ($J_{\text{CH}} = 139.0$ Hz, Man-IV). HR ESI MS data for β -isomer are consistent with α -isomer.

Phenyl [2,3,4,6-tetra-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[6-*O*-(*tert*-butyldiphenylsilyl)-3,4-di-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[3,4,6-tri-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 6)-3,4-di-*O*-(*p*-methoxybenzyl)-1-thio- α -D-mannopyranoside (23)

To a solution of α,β -mixture **22** (1.3 g, which also contained some inseparable impurity from the previous glycosylation) in anhydrous THF (30 mL) was added titanium(IV) isopropoxide (0.76 g in 5.0 mL hexanes, 2.7 mmol). To the reaction mixture, cyclopentylmagnesium chloride (2.87 M solution in Et_2O , 1.86 mL, 5.36 mmol) was added dropwise under an Ar atmosphere at rt over a period of 1 h. After stirring an additional 2 h, the reaction mixture was poured into water. The mixture was extracted three times with CH_2Cl_2 , and then the combined organic layer was washed with brine, dried over Na_2SO_4 , and concentrated under vacuum. The resulting residue was purified by silica gel column chromatography (toluene- EtOAc 5:1) to give **23** (0.895 g, 78% over two steps). At this stage, the α,β -mixture was purified by semi-preparative HPLC (Waters Nova-Pak Silica 6 μm , 300 $\times$ 19 mm, eluent 35% acetone in hexanes, 10 mL/min, **23** $t_{\text{R}} = 36.19$ min, β -isomer of **23** $t_{\text{R}} = 38.78$ min), which showed an anomeric ratio of 3:2. Characterization data for **23**: ^1H NMR (CDCl_3 , 500 MHz): δ 7.74 (dd, $J = 6.4, 1.8$ Hz, 2 H), 7.69 (dd, $J = 7.6, 1.8$ Hz, 2 H), 7.33-7.26 (m, 11 H), 7.24-7.22 (m, 6 H), 7.19-7.15 (m, 5 H), 7.13-7.11 (m, 7 H), 7.08 (d, $J = 8.5$ Hz, 2 H), 7.04 (d, $J = 8.5$ Hz, 2 H), 7.02 (d, $J = 7.32$ Hz, 1 H), 6.90 (d, $J = 8.8$ Hz, 2 H), 6.83-6.78 (m, 9 H), 6.76-6.73 (m, 10 H), 5.39 (br s, 1 H, Man-I 1-position), 5.37 (br s, 1 H, Man-III 1-position), 5.30 (br s, 1 H, Man-IV 1-position), 4.86 (d, $J = 1.2$ Hz, 1 H, Man-II 1-position), 4.83 (d, $J = 10.4$ Hz, 1 H), 4.78 (d, $J = 9.5$ Hz, 1 H), 4.76 (d, $J = 10.4$ Hz, 1 H), 4.72 (d, $J = 10.7$ Hz, 1 H), 4.62-4.57 (m, 5 H), 4.56 (d, $J = 10.4$ Hz, 1 H), 4.52 (d, $J = 10.4$ Hz, 1 H), 4.50 (d, $J = 10.4$ Hz, 1 H), 4.49 (d, $J = 10.7$ Hz, 1 H), 4.43-4.34 (m, 8 H), 4.29-4.26 (m, 2 H), 4.15-4.08 (m, 3 H), 4.02-3.93 (m, 4 H), 3.90-3.86 (m, 4 H), 3.85-3.83 (m, 3 H), 3.83 (s, 3 H), 3.80 (s, 3 H), 3.80 (s, 3 H), 3.79-3.76 (m, 2 H), 3.78 (s, 3 H), 3.76-3.74 (m, 1 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.73 (s, 3 H), 3.72 (s, 3 H), 3.70 (s, 3 H), 3.67 (s, 3 H), 3.67-3.65 (m, 2 H), 3.61-3.59 (m, 2 H), 3.57 (s, 3 H), 3.55-3.50 (m, 2 H), 2.64 (br s, 1 H), 1.00 (s, 9 H). ^{13}C NMR (CDCl_3 , 125 MHz): δ 159.7, 159.4, 159.30, 159.28, 159.22, 159.17, 159.12, 159.08, 136.1, 135.9, 134.6, 134.1, 133.5, 131.4, 131.23, 131.20, 131.16, 130.9, 130.82, 130.76, 130.62, 130.60, 130.0, 129.92, 129.87, 129.8, 129.65, 129.62, 129.58, 129.54, 129.52, 129.3, 129.2, 127.92, 127.86, 127.3, 114.2, 114.1, 114.0, 113.95, 113.90, 113.85, 113.80, 113.76, 113.7, 100.2 (Man-III), 99.58 (Man-IV), 99.58 (Man-II), 87.5 (Man-I), 80.4, 80.2, 80.1, 79.3, 75.0, 74.93, 74.87, 74.7, 74.6, 74.54, 74.47,

74.3, 73.9, 73.5, 73.2, 73.0, 72.6, 72.5, 72.4, 72.24, 72.19, 71.9, 71.83, 71.76, 71.3, 69.9, 69.0, 68.8, 66.4, 63.4, 55.53, 55.52, 55.49, 55.46, 55.41, 55.40, 55.38, 55.36, 55.32, 55.24, 27.2, 19.5. ^{13}C NMR J_{CH} values (125 MHz): 100.2 ($J_{\text{CH}} = 172.5$ Hz, Man-III), 99.58 ($J_{\text{CH}} = 172.5$ Hz, Man-IV), 99.58 ($J_{\text{CH}} = 172.5$ Hz, Man-II), 87.5 ($J_{\text{CH}} = 166.0$ Hz, Man-I). $[\alpha]_{\text{D}}^{25} = +49.8^\circ$ (c 0.5, CHCl_3). HRMS (ESI): calcd. for $\text{C}_{134}\text{H}_{152}\text{NaO}_{31}\text{SSi}$ $[\text{M}+\text{Na}]^+$ m/z , 2339.9705; found, 2339.9761.

Phenyl [2,3,4,6-tetra-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[6-*O*-(*tert*-butyldiphenylsilyl)-3,4-di-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[3,4,6-tri-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 6)-3,4-di-*O*-(*p*-methoxybenzyl)-2-*O*-triethylsilyl-1-thio- α -D-mannopyranoside (24)

TESOTf (29 μL , 0.13 mmol) was added slowly to a solution of tetramannose **23** (20 mg, 8.6 μmol) and triethylamine (36 μL , 0.26 mmol) in anhydrous CH_2Cl_2 (1.5 mL) stirring under Ar at 0 $^\circ\text{C}$. After stirring the reaction mixture for 2 h while warming to rt, it was poured into saturated aqueous NaHCO_3 , which was then extracted three times with CH_2Cl_2 . The combined organic layer was dried over Na_2SO_4 , concentrated under vacuum, and purified by silica gel column chromatography (toluene-EtOAc 8:1) to afford **24** (16 mg, 76%) as syrup. ^1H NMR (CDCl_3 , 500 MHz): δ 7.77 (dd, $J = 6.4$, 1.5 Hz, 2 H), 7.73 (dd, $J = 7.6$, 1.5 Hz, 2 H), 7.45-7.42 (m, 3 H), 7.40-7.30 (m, 9 H), 7.28-7.21 (m, 6 H), 7.22-7.15 (m, 7 H), 7.16-7.12 (m, 5 H), 7.10-7.02 (m, 5 H), 6.91 (d, $J = 8.5$ Hz, 2 H), 6.87-6.81 (m, 7 H), 6.81-6.76 (m, 8 H), 6.76-6.74 (m, 3 H), 5.42 (br s, 1 H, Man-III 1-position), 5.34 (d, $J = 1.2$ Hz, 1 H, Man-IV 1-position), 5.31 (d, $J = 1.2$ Hz, 1 H, Man-I 1-position), 4.85 (d, $J = 1.2$ Hz, 1 H, Man-II 1-position), 4.84 (d, $J = 10.4$ Hz, 1 H), 4.81 (d, $J = 10.4$ Hz, 1 H), 4.79 (d, $J = 11.0$ Hz, 1 H), 4.78 (d, $J = 11.0$ Hz, 1 H), 4.69 (d, $J = 11.3$ Hz, 1 H), 4.66 (d, $J = 11.9$ Hz, 1 H), 4.64 (d, $J = 11.6$ Hz, 1 H), 4.62 (d, $J = 11.6$ Hz, 1 H), 4.60 (d, $J = 11.6$ Hz, 1 H), 4.58 (d, $J = 11.0$ Hz, 1 H), 4.56 (d, $J = 10.4$ Hz, 1 H), 4.55 (d, $J = 11.3$ Hz, 1 H), 4.54 (d, $J = 11.9$ Hz, 1 H), 4.52 (d, $J = 11.0$ Hz, 1 H), 4.46 (d, $J = 10.7$ Hz, 1 H), 4.43 (d, $J = 10.4$ Hz, 1 H), 4.42 (d, $J = 10.4$ Hz, 1 H), 4.42 (d, $J = 11.0$ Hz, 1 H), 4.41 (d, $J = 10.4$ Hz, 1 H), 4.40 (d, $J = 10.4$ Hz, 1 H), 4.38 (d, $J = 10.7$ Hz, 1 H), 4.37 (d, $J = 11.0$ Hz, 1 H), 4.29 (d, $J = 2.0$ Hz, 2 H), 4.27 (br s, 1 H), 4.20 (t, $J = 7.6$ Hz, 1 H), 4.15 (dd, $J = 2.0$, 1.5 Hz, 1 H), 4.06 (t, $J = 9.5$ Hz, 1 H), 4.01-3.95 (m, 3 H), 3.95-3.91 (m, 3 H), 3.91-3.86 (m, 5 H), 3.84 (s, 3 H), 3.83 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.81-3.77 (m, 3 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.75 (s, 3 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.69 (s, 3 H), 3.69-3.65 (m, 2 H), 3.60 (s, 3 H), 3.60-3.53 (m, 2 H), 1.03 (s, 9 H), 0.95 (t, $J = 7.9$ Hz, 9 H), 0.60 (distorted q, $J = 7.9$ Hz, 6 H). ^{13}C NMR (CDCl_3 , 125 MHz): δ 159.4, 159.35, 159.33, 159.24, 159.21, 159.18, 159.13, 159.12, 136.1, 135.9, 135.3, 134.1, 133.4, 131.5, 131.32, 131.27, 131.15, 131.12, 130.9, 130.80, 130.78, 130.7, 130.62, 130.59, 129.9, 129.80, 129.78, 129.7, 129.64, 129.58, 129.55, 129.54, 129.4, 129.31, 129.26, 128.0, 127.9, 127.3, 114.1, 114.02, 113.99, 113.96, 113.91, 113.88, 113.86, 113.79, 113.75, 100.2 (Man-III), 99.6 (Man-IV), 99.2 (Man-II), 89.7 (Man-I), 80.7, 80.15, 80.14, 80.10, 75.03, 74.97, 74.7, 74.6, 74.5, 74.4, 74.3, 73.7, 73.2, 72.9, 72.55, 72.49, 72.4, 72.2, 72.1, 72.0, 71.7, 71.5, 71.4, 68.8, 68.6, 67.0, 63.4, 55.52, 55.51, 55.49, 55.46, 55.42, 55.40, 55.39, 55.33, 55.2, 27.2, 19.5, 7.2, 5.3. $[\alpha]_{\text{D}}^{25} = +40.0^\circ$ (c 0.5, CHCl_3). HRMS (ESI): calcd. for $\text{C}_{140}\text{H}_{166}\text{NaO}_{31}\text{SSi}_2$ $[\text{M}+\text{Na}]^+$ m/z , 2454.0570; found, 2454.0669.

[2,3,4,6-tetra-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[6-*O*-(*tert*-butyldiphenylsilyl)-3,4-di-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[3,4,6-tri-*O*-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 6)-3,4-di-*O*-(*p*-methoxybenzyl)-2-*O*-triethylsilyl-D-mannopyranose (25)

To a solution of tetramannose thioglycoside **24** (88 mg, 0.036 mmol) in wet CH_2Cl_2 (5 mL) at 0 $^\circ\text{C}$ was added 2,4,6-tri-*tert*-butylpyrimidine (26 mg, 0.11 mmol), *N*-iodosuccinimide (16 mg, 0.07 mmol), and silver triflate (18 mg, 0.07 mmol). After stirring for 2 h at rt, saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ was added at 0 $^\circ\text{C}$ and the reaction mixture was stirred for an additional

30 min while warming to rt. The reaction mixture was extracted three times with CH₂Cl₂, and the combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (toluene-EtOAc 5:1) to afford tetramannose hemiacetal **25** (78 mg, 92%) as syrup. ¹H NMR (CDCl₃, 500 MHz): δ 7.78 (dd, *J* = 7.3, 1.5 Hz, 2 H), 7.75 (dd, *J* = 7.0, 1.5 Hz, 2 H), 7.39-7.32 (m, 8 H), 7.31-7.24 (m, 8 H), 7.22-7.19 (m, 5 H), 7.18-7.12 (m, 5 H), 7.06 (dd, *J* = 8.5, 2.7 Hz, 4 H), 6.87 (d, *J* = 8.8 Hz, 2 H), 6.85 (d, *J* = 7.9 Hz, 2 H), 6.84 (d, *J* = 7.9 Hz, 2 H), 6.83 (d, *J* = 7.0 Hz, 2 H), 6.82 (d, *J* = 7.0 Hz, 2 H), 6.81-6.75 (m, 10 H), 5.33 (br s, 1 H, Man-III 1-position), 5.28 (br s, 1 H, Man-IV 1-position), 4.85 (d, *J* = 2.1 Hz, 1 H, Man-II 1-position), 4.84 (d, *J* = 10.4 Hz, 1 H), 4.83 (br s, 1 H, Man-I 1-position), 4.79 (d, *J* = 10.7 Hz, 1 H), 4.75 (d, *J* = 10.7 Hz, 1 H), 4.68 (d, *J* = 10.7 Hz, 1 H), 4.65 (d, *J* = 11.3 Hz, 1 H), 4.62 (d, *J* = 11.6 Hz, 1 H), 4.60 (d, *J* = 11.0 Hz, 1 H), 4.58-4.51 (m, 6 H), 4.50-4.38 (m, 6 H), 4.33 (d, *J* = 10.4 Hz, 1 H), 4.31 (d, *J* = 11.3 Hz, 1 H), 4.29 (d, *J* = 11.9 Hz, 1 H), 4.25 (d, *J* = 10.4 Hz, 1 H), 4.21 (dd, *J* = 2.0, 1.2 Hz, 1 H), 4.12 (dd, *J* = 2.5, 1.5 Hz, 1 H), 4.00-3.94 (m, 5 H), 3.93-3.85 (m, 6 H), 3.82 (s, 3 H), 3.82 (s, 3 H), 3.81 (s, 3 H), 3.80 (s, 3 H), 3.79-3.77 (m, 3 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.74 (s, 3 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.72 (s, 3 H), 3.68 (s, 3 H), 3.67-3.60 (m, 5 H), 3.59-3.51 (m, 2 H), 2.39 (br s, 1 H), 1.05 (s, 9 H), 0.95 (t, *J* = 7.9 Hz, 9 H), 0.58 (distorted q, *J* = 7.6 Hz, 6 H). ¹³C NMR (CDCl₃, 125 MHz): δ 159.43, 159.40, 159.36, 159.32, 159.26, 159.22, 159.19, 159.17, 159.14, 136.2, 135.9, 134.1, 133.4, 131.3, 131.2, 131.1, 130.9, 130.81, 130.76, 130.5, 129.8, 129.75, 129.70, 129.67, 129.64, 129.5, 129.3, 128.0, 127.9, 114.05, 114.01, 113.95, 113.93, 113.90, 113.82, 113.79, 113.77, 99.70 (Man-III), 99.70 (Man-IV), 99.5 (Man-II), 95.1 (Man-I), 80.1, 80.0, 74.9, 74.85, 74.77, 74.7, 74.5, 73.4, 73.2, 73.0, 72.5, 72.4, 72.2, 72.0, 71.9, 71.85, 71.80, 70.4, 69.6, 69.1, 68.8, 63.3, 55.49, 55.48, 55.46, 55.43, 55.40, 55.37, 55.35, 27.2, 19.5, 7.2, 5.2. HRMS (ESI): calcd. for C₁₃₄H₁₆₂NaO₃₂Si₂ [M+Na]⁺ *m/z*, 2362.0485; found, 2362.0591.

6-O-[[2,3,4,6-tetra-O-(*p*-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4-di-O-(*p*-methoxybenzyl)-α-D-mannopyranosyl]-(1→2)-[3,4,6-tri-O-(*p*-methoxybenzyl)-α-D-mannopyranosyl]-(1→6)-[3,4-di-O-(*p*-methoxybenzyl)-α-D-mannopyranosyl]-(1→4)-[2-azido-2-deoxy-3,6-di-O-(*p*-methoxybenzyl)-α-D-glucopyranosyl]]-1-O-[(2-cyanoethoxy)-(2-O-arachidonoyl-3-O-stearoyl-*sn*-glycerol)-phosphono]-2,3,4,5-tetra-O-(*p*-methoxybenzyl)-myo-inositol (26)

To a solution of tetramannose hemiacetal **25** (78 mg, 0.03 mmol) in anhydrous CH₂Cl₂ (5 mL) was added DBU (1 drop) and trichloroacetoneitrile (0.3 mL). After stirring under an Ar atmosphere at 0 °C for 30 min, the reaction mixture was concentrated under vacuum and purified with a triethylamine-treated neutral silica gel column to furnish tetramannose donor **3** (82 mg, 99%). A mixture of the resulting trichloroacetimidate **3** (44 mg, 0.02 mmol), acceptor **2** (10 mg, 5.95 μmol), and MS 4 A (10 mg) in anhydrous Et₂O (4 mL) was stirred under an Ar atmosphere at rt for 1 h. The reaction mixture was cooled to 0 °C, TMSOTf (0.05 M solution in anhydrous Et₂O, 40 μL) was added, and the reaction was stirred overnight while warming to rt. The reaction was neutralized by addition of saturated aqueous NaHCO₃. After filtration through a celite pad to remove MS 4 Å, the mixture was extracted three times with CH₂Cl₂, and the combined organic layer was dried over Na₂SO₄ and concentrated under vacuum. The residue was partially purified by silica gel column chromatography to give the intermediate α-pseudoexasaccharide, which was taken directly to the next step. To a solution of the crude material (13.7 mg) in anhydrous THF-CH₃CN (1:1, 1 mL) was added Et₃N·3HF (0.5 mL) under an Ar atmosphere at rt. After stirring 7 days at rt, the reaction was quenched by dropwise addition of saturated aqueous NaHCO₃ at 0 °C. The aqueous layer was extracted three times with CH₂Cl₂, and the combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by silica gel column chromatography (toluene-EtOAc 2.5:1) to give

diol **26** (8.1 mg, 39% for two steps) as syrup. ^1H NMR (CDCl_3 , 500 MHz): δ 7.34-7.26 (m, 10 H), 7.25-7.15 (m, 15 H), 7.13-7.07 (m, 9 H), 7.02 (d, $J = 8.5$ Hz, 2 H), 6.89-6.84 (m, 8 H), 6.81-6.78 (m, 8 H), 6.76-6.72 (m, 16 H), 5.43-5.30 (m, 8 H), 5.36 (d, $J = 3.7$ Hz, 1 H, GlcN₃ 1-position), 5.30-5.26 (m, 1 H, glyceride CH), 5.21 (d, $J = 2.4$ Hz, 1 H, Man-III 1-position), 5.21 (d, $J = 2.4$ Hz, 1 H, Man-IV 1-position), 5.13 (br s, 1 H, Man-I 1-position), 4.97 (d, $J = 11.0$ Hz, 1 H), 4.96 (br s, 1 H, Man-II 1-position), 4.92 (dd, $J = 10.4$, 2.5 Hz, 1 H), 4.85 (d, $J = 10.4$ Hz, 1 H), 4.84 (d, $J = 9.2$ Hz, 1 H), 4.81-4.71 (m, 5 H), 4.69-4.62 (m, 4 H), 4.60-4.56 (m, 4 H), 4.56-4.50 (m, 4 H), 4.49-4.45 (m, 5 H), 4.44-4.39 (m, 4 H), 4.39-4.34 (m, 4 H), 4.33-4.30 (m, 2 H), 4.29-4.27 (m, 2 H), 4.25-4.15 (m, 8 H), 4.04-3.96 (m, 4 H), 3.86-3.81 (m, 7 H), 3.82 (s, 3 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.77 (s, 3 H), 3.77 (s, 3 H), 3.76 (s, 3 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.73 (s, 3 H), 3.72 (s, 3 H), 3.70 (s, 3 H), 3.70 (s, 3 H), 3.70-3.67 (m, 2 H), 3.67 (s, 3 H), 3.66-3.64 (m, 3 H), 3.63 (s, 3 H), 3.61 (s, 3 H), 3.62-3.56 (m, 2 H), 3.57 (s, 3 H), 3.57-3.52 (m, 3 H), 3.51-3.43 (m, 4 H), 3.40-3.36 (m, 2 H), 3.36 (s, 3 H), 3.22 (dd, $J = 10.7$, 2.1 Hz, 1 H), 3.16 (dd, $J = 9.8$, 3.7 Hz, 1 H), 3.09 (ddd, $J = 10.7$, 2.1, 0.9 Hz, 1 H), 2.84-2.77 (m, 6 H), 2.68-2.63 (m, 2 H), 2.59 (br s, 1 H), 2.37-2.32 (m, 2 H), 2.30-2.26 (m, 2 H), 2.12-2.08 (m, 2 H), 2.08-2.03 (m, 2 H), 1.72-1.65 (m, 3 H), 1.61-1.55 (m, 2 H), 1.39-1.33 (m, 4 H), 1.32-1.22 (m, 30 H), 0.91-0.87 (m, 6 H). ^{13}C NMR (CDCl_3 , 125 MHz): δ 173.5, 172.9, 159.6, 159.4, 159.35, 159.32, 159.26, 159.22, 159.17, 159.15, 159.14, 131.09, 131.07, 131.02, 130.92, 130.89, 130.84, 130.7, 130.6, 130.49, 130.47, 130.3, 129.87, 129.83, 129.81, 129.80, 129.77, 129.75, 129.74, 129.72, 129.6, 129.5, 129.3, 129.25, 129.22, 129.1, 129.0, 128.8, 128.6, 128.5, 128.3, 128.1, 127.7, 116.6, 114.12, 114.10, 114.05, 114.04, 114.01, 113.96, 113.93, 113.90, 113.84, 113.83, 113.79, 113.70, 101.9 (Man-III), 100.5 (Man-I), 99.3 (Man-IV), 99.2 (Man-II), 98.0 (GlcN₃), 81.4, 80.7, 80.6, 79.8, 79.7, 79.5, 79.4, 78.5, 76.42, 76.41, 75.65, 75.56, 75.3, 75.0, 74.9, 74.7, 74.65, 74.59, 74.5, 74.3, 74.2, 73.90, 73.88, 73.6, 73.19, 73.15, 73.13, 73.0, 72.8, 72.58, 72.53, 72.48, 72.40, 71.8, 71.64, 71.59, 71.4, 70.05, 70.01, 69.7, 69.0, 68.8, 68.7, 68.2, 66.5, 66.0, 64.9, 63.25, 63.23, 62.51, 62.48, 62.45, 62.40, 62.37, 61.7, 55.51, 55.48, 55.46, 55.44, 55.42, 55.40, 55.37, 55.35, 55.33, 55.27, 55.23, 55.20, 41.3, 34.2, 33.8, 32.2, 31.7, 30.0, 29.9, 29.8, 29.62, 29.58, 29.4, 27.5, 26.70, 26.67, 26.65, 25.9, 25.8, 25.1, 24.9, 22.9, 22.8, 19.85, 19.78, 14.4, 14.3. Configurations of anomeric positions were established as α by coupled ^{13}C NMR J_{CH} values (125 MHz): 101.9 ($J_{\text{CH}} = 179.7$ Hz, Man-III), 100.5 ($J_{\text{CH}} = 173.4$ Hz, Man-I), 99.3 ($J_{\text{CH}} = 178.1$ Hz, Man-IV), 99.2 ($J_{\text{CH}} = 178.1$ Hz, Man-II). ^{31}P NMR (CDCl_3 , 160 MHz): δ -1.79. $[\alpha]_{\text{D}}^{25} = +43.0^\circ$ (c 0.4, CHCl_3). HRMS (ESI): calcd. for $\text{C}_{216}\text{H}_{271}\text{N}_4\text{NaO}_{54}\text{P}$ $[\text{M}+\text{Na}]^+$ m/z , 3838.8218; found, 3838.8269.

6-O-[[2,3,4,6-tetra-O-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[6-O-[(2-cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]-phosphono]]-3,4-di-O-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 2)-[3,4,6-tri-O-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 6)-[2-O-[(2-Cyanoethoxy)-[2-(9-fluorenylmethoxycarbonylamino)ethyl]-phosphono]]-3,4-di-O-(*p*-methoxybenzyl)- α -D-mannopyranosyl]-(1 $\rightarrow$ 4)-[2-azido-2-deoxy-3,6-di-O-(*p*-methoxybenzyl)- α -D-glucopyranosyl]-1-O-[(2-cyanoethoxy)-(2-O-arachidonoyl-3-O-stearoyl-*sn*-glycerol)-phosphono]-2,3,4,5-tetra-O-(*p*-methoxybenzyl)-*myo*-inositol (27**)**

To a stirring solution of pseudohexasaccharide **26** (4.1 mg, 1.0 μmol) and MS 4 A (5 mg) in anhydrous CH_2Cl_2 - CH_3CN (3:1, 1.5 mL) was added freshly prepared phosphoramidite **4** (15.5 mg in 500 μL dry CH_2Cl_2 , 0.03 mmol). Then, 1*H*-tetrazole (0.45 M solution in acetonitrile, 143 μL , 0.06 mmol) was added under Ar at rt. After stirring the reaction mixture at rt under Ar overnight, it was cooled to -40°C and treated with *tert*-butyl hydroperoxide (5.5 M solution in decane 23 μL , 0.13 mmol). The solution was further stirred for 1 h at -40°C , after which Me_2S (19 μL , 0.26 mmol) was added and stirring continued for an additional 1 h at -40°C . After passage through a celite pad to remove MS 4 Å, the mixture was poured into saturated aqueous NaHCO_3 and extracted three times with

CH₂Cl₂. The combined organic layer was dried over Na₂SO₄ and concentrated under vacuum. Purification of the crude material by silica gel column chromatography afforded diphosphorylated GPI **27** and also the Man-III monophosphorylated GPI. Both compounds were further purified using Sephadex LH-20 size exclusion chromatography (CHCl₃-MeOH, 3:1) to provide **27** (1.85 mg, 37%) and the Man-III monophosphorylated compound (0.7 mg, 15%), which both existed as complex diastereomeric mixtures resulting from the newly formed stereogenic phosphates. This was inconsequential as the following global deprotection step rendered the phosphorus atoms non-stereogenic. **27**: ¹H NMR (CDCl₃, 500 MHz, resolved signals): δ 7.73-7.70 (m, 4 H), 7.55-7.48 (m, 4 H), 7.40-7.28 (m, 10 H), 7.26-7.19 (m, 12 H), 7.18-7.10 (m, 12 H), 7.09-7.04 (m, 4 H), 7.01-6.95 (m, 4 H), 7.00-6.95 (m, 4 H), 6.80-6.69 (m, 24 H), 5.55 (br s, 1 H, Man-I 1-position), 5.41-5.31 (m, 8 H), 5.35 (br s, 1 H, GlcN₃ 1-position), 5.30-5.26 (m, 1 H, glyceride CH), 5.10 (s, 1 H, Man-III 1-position), 4.88 (s, 1 H, Man-IV 1-position), 4.84 (s, 1 H, Man-II 1-position), 2.84-2.76 (m, 6 H), 2.64-2.58 (m, 2 H), 2.33-2.20 (m, 8 H), 2.08-2.00 (m, 4 H), 1.72-1.54 (m, 4 H), 1.38-1.20 (m, 34 H), 0.90-0.87 (m, 6 H). ³¹P NMR (CDCl₃, 160 MHz): δ -0.78, -0.82, -1.26, -1.29, -1.64, -1.65, -1.85, -2.25, -2.26, -2.69, -2.71, -3.00, -3.05. MALDI TOF MS (positive mode): calcd. For C₂₅₆H₃₁₀N₈NaO₆₄P₃ [M+H+Na]⁺ m/z, 4636.0; found, 4636.5. Monophosphorylated compound: ¹H-NMR (CDCl₃, 500 MHz, resolved signals): δ 7.73-7.70 (m, 2 H), 7.53-7.51 (m, 2 H), 7.36-7.28 (m, 10 H), 7.26-7.21 (m, 6 H), 7.20-7.13 (m, 10 H), 7.12-7.05 (m, 8 H), 7.04-6.98 (m, 4 H), 6.90-6.82 (m, 10 H), 6.81-6.70 (m, 24 H), 5.40-5.30 (m, 9 H, includes glyceride CH), 5.24 (br s, 2 H), 5.15 (br s, 2 H), 4.95 (br s, 1 H), 2.83-2.77 (m, 6 H), 2.65-2.60 (m, 2 H), 2.35-2.21 (m, 6 H), 2.07-2.00 (m, 4 H), 1.70-1.55 (m, 4 H), 1.37-1.20 (m, 34 H), 0.90-0.85 (m, 6 H). ³¹P NMR (CDCl₃, 160 MHz): δ -0.72, -1.29, -2.14, -2.30, -2.62, -2.64, -2.91, -2.99. MALDI TOF MS (positive mode): calcd. For C₂₃₆H₂₉₂N₆NaO₅₉P₂ [M+2H+Na]⁺ m/z, 4238.9; found, 4238.4.

6-O-[[α-D-Mannopyranosyl]-(1→2)-[6-O-[(2-aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→2)-[α-D-mannopyranosyl]-(1→6)-[2-O-[(2-aminoethyl)-phosphono]-α-D-mannopyranosyl]-(1→4)-[2-amino-2-deoxy-α-D-glucopyranosyl]]-1-O-[(2-O-arachidonoyl-3-O-stearoyl-sn-glycerol)-phosphono]-myo-inositol (1)

To a solution of pseudohexasaccharide **27** (1.85 mg, 0.40 μmol) in CH₂Cl₂ (500 μL) was added acetic acid (1 drop) and zinc powder (10 mg). After vigorously stirring for 1 h at rt, MALDI TOF MS showed complete reduction of the azide [MALDI TOF MS (positive mode): calcd. For C₂₅₆H₃₁₁N₆NaO₆₄P₃ [M+Na]⁺ m/z, 4609.0; found, 4609.0]. The mixture was filtered through a celite plug and condensed in vacuum to remove acetic acid, and the resulting residue was re-dissolved in CH₂Cl₂ (500 μL) and treated with DBU (2 μL). The solution stirred for 1 h, after which MALDI TOF MS confirmed removal of the Fmoc and cyanoethoxyl protecting groups [MALDI TOF MS (negative mode): calcd. For C₂₁₇H₂₈₁N₃O₆₀P₃ [M-H]⁻ m/z 3981.8; found, 3981.6]. Then, 20% TFA in CH₂Cl₂ (500 μL) was added directly to the reaction mixture at 0 °C, giving a final concentration of ~10% TFA. After stirring for 30 min at rt, the reaction was co-evaporated with toluene 5 times. Purification of the crude product by Sephadex LH-20 size exclusion chromatography (CHCl₃/MeOH/H₂O, 3:3:1) afforded GPI **1** (0.70 mg, 90%). ¹H NMR (CDCl₃/CD₃OD/D₂O 3:3:1, 500 MHz, anomeric region): δ 5.46 (1 H Man-I), 5.42-5.32 (8 H, arachidonoyl lipid sp²-CH), 5.25 (1 H, glyceride CH), 5.24 (1 H, GlcNH₂-1), 5.04 (1 H, Man-III), 4.98 (1 H, Man-IV), 4.98 (1 H, Man-II). ¹³C NMR (CDCl₃/CD₃OD/D₂O 3:3:1, 125 MHz, anomeric region): δ 100.3 (Man-IV), 100.3 (Man-II), 101.5 (GlcNH₂-1), 99.5 (Man-III), 97.5 (Man-I). ³¹P NMR (CDCl₃, 160 MHz): δ 4.37, 3.59, 3.51. MALDI TOF MS (negative mode): calcd. For C₈₁H₁₄₅N₃O₄₃P₃ [M-H]⁻ m/z 1940.8; found, 1940.7.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded by NIH (R01GM090270). We thank Dr. B. Shay and Dr. L. Hryhorczuk for MS measurements, and Dr. B. Ksehati for help with some NMR experiments.

References

1. a) Ferguson MAJ, Williams AF. *Annu Rev Biochem.* 1988; 57:121–138. b) Englund PT. *Annu Rev Biochem.* 1993; 62:121–138. [PubMed: 8352586] c) Ikezawa H. *Biol Pharm Bull.* 2002; 25:409–417. [PubMed: 11995915] d) Paulick MG, Bertozzi CR. *Biochemistry.* 2008; 47:6991–7000. [PubMed: 18557633]
2. He HT, Finne J, Goridis C. *J Cell Biol.* 1987; 105:2489–2500. [PubMed: 3693391]
3. a) Robinson PJ, Millrain M, Antoniou J, Simpson E, Mellor AL. *Nature.* 1989; 342:85–87. [PubMed: 2530453] b) Eardley DD, Koshland ME. *Science.* 1991; 251:78–81. [PubMed: 1824727]
4. Kinoshita, T.; Inoue, N.; Takeda, J. *Adv Immunol.* Frank, JD., editor. Vol. 60. Academic Press; 1995. p. 57–103.
5. Ferguson MAJ, Homans SW, Dwek RA, Rademacher TW. *Science.* 1988; 239:753–759. [PubMed: 3340856]
6. a) Masterson WJ, Raper J, Doering TL, Hart GW, Englund PT. *Cell.* 1990; 62:73–80. [PubMed: 1694728] b) Reggiori F, Canivenc-Gansel E, Conzelmann A. *EMBO J.* 1997; 16:3506–3518. [PubMed: 9218793] c) Ralton JE, McConville MJ. *J Biol Chem.* 1998; 273:4245–4257. [PubMed: 9461623] d) Fujita M, Jigami Y. *Biochim Biophys Acta.* 2008; 1780:410–420. [PubMed: 17913366]
7. a) Roberts WL, Myher JJ, Kuksis A, Low MG, Rosenberry TL. *J Biol Chem.* 1988; 263:18766–18775. [PubMed: 2848806] b) Treumann A, Lifely MR, Schneider P, Ferguson MAJ. *J Biol Chem.* 1995; 270:6088–6099. [PubMed: 7890742]
8. Maeda Y, Tashima Y, Houjou T, Fujita M, Yoko-o T, Jigami Y, Taguchi R, Kinoshita T. *Mol Biol Cell.* 2007; 18:1497–1506. [PubMed: 17314402]
9. Almeida IC, Camargo MM, Procópio DO, Silva LS, Mehler A, Travassos LR, Gazzinelli RT, Ferguson MAJ. *EMBO J.* 2000; 19:1476. [PubMed: 10747016]
10. Schröter S, Derr P, Conradt HS, Nimtz M, Hale G, Kirchhoff C. *J Biol Chem.* 1999; 274:29862–29873. [PubMed: 10514467]
11. a) Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. *Tissue Antigens.* 1990; 35:118–127. [PubMed: 2165283] b) Diekman AB, Norton EJ, Klotz KL, Westbrook VA, Shibahara H, Naaby-Hansen S, Flickinger CJ, Herr JC. *FASEB J.* 1999; 13:1303–1313. [PubMed: 10428755] c) Eccleston ED, White TW, Howard JB, Hamilton DW. *Mol Reprod Dev.* 1994; 37:110–119. [PubMed: 8129926]
12. Gribben JG, Hallek M. *Brit J Haematol.* 2009; 144:818–831. [PubMed: 19183194]
13. Tsuji Y, Clausen H, Nudelman E, Kaizu T, Hakomori SI, Isojima S. *J Exp Med.* 1988; 168:343–356. [PubMed: 3294333]
14. a) Murakata C, Ogawa T. *Carbohydr Res.* 1992; 235:95–114. [PubMed: 1473115] b) Mayer TG, Kratzer B, Schmidt RR. *Angew Chem Int Ed Engl.* 1994; 33:2177–2181. c) Campbell AS, Fraser-Reid B. *J Am Chem Soc.* 1995; 117:10387–10388. d) Baeschlin DK, Chaperon AR, Charbonneau V, Green LG, Ley SV, Lücking U, Walther E. *Angew Chem Int Ed Engl.* 1998; 37:3423–3428. e) Liu X, Kwon YU, Seeberger PH. *J Am Chem Soc.* 2005; 127:5004–5005. [PubMed: 15810819] f) Yashunsky DV, Borodkin VS, Ferguson MAJ, Nikolaev AV. *Angew Chem Int Ed Engl.* 2006; 45:468–474. [PubMed: 16342127] g) Becker C, Liu X, Olschewski D, Castelli R, Seidel R, Seeberger P. *Angew Chem Int Ed Engl.* 2008; 47:8215–8219. [PubMed: 18814158] h) Guo Z, Bishop L. *Eur J Org Chem.* 2004:3585–3596. i) Nikolaev AV, Al-Maharik N. *Nat Prod Rep.* 2011; 28:970–1020. [PubMed: 21448495]

15. a) Xue J, Guo Z. *J Am Chem Soc.* 2003; 125:16334–16339. [PubMed: 14692775] b) Wu X, Guo Z. *Org Lett.* 2007; 9:4311–4313. [PubMed: 17877362] c) Wu Z, Guo X, Wang Q, Swarts BM, Guo Z. *J Am Chem Soc.* 2010; 132:1567–1571. [PubMed: 20078124] d) Swarts BM, Guo Z. *J Am Chem Soc.* 2010; 132:6648–6650. [PubMed: 20423078] e) Swarts BM, Guo Z. *Chem Sci.* 2011; 10.1039/c1031sc00440a
16. a) Shao N, Xue J, Guo Z. *Angew Chem Int Ed Engl.* 2004; 43:1569–1573. [PubMed: 15022236] b) Swarts BM, Chang YC, Hu H, Guo Z. *Carbohydr Res.* 2008; 343:2894–2902. [PubMed: 18789797]
17. Schmidt RR, Michel J. *Angew Chem Int Ed Engl.* 1980; 19:731–732.
18. a) Han L, Razdan RK. *Tetrahedron Lett.* 1999; 40:1631–1634. b) Seltzman HH, Fleming DN, Hawkins GD, Carroll FI. *Tetrahedron Lett.* 2000; 41:3589–3592. c) Cartoni A, Margonelli A, Angelini G, Finazzi-Agrò A, Maccarrone M. *Tetrahedron Lett.* 2004; 45:2723–2726.
19. Garegg PJ, Maron L. *Acta Chem Scand, Ser B.* 1979; B33:39–41.
20. Mootoo DR, Konradsson P, Udodong U, Fraser-Reid B. *J Am Chem Soc.* 1988; 110:5583–5584.
21. Lee J, Cha JK. *Tetrahedron Lett.* 1996; 37:3663–3666.
22. Bock K, Pedersen C. *J Chem Soc, Perkin Trans.* 1974; 2:293–297.

Scheme 1.

Retrosynthesis of lymphocyte CD52 GPI anchor **1**. Ac = acetyl, All = allyl, Arach = arachidonoyl, Fmoc = 9 fluorenylmethoxycarbonyl, Stear = stearoyl, TBDPS = *tert*-butyldiphenylsilyl, TES = triethylsilyl.

Scheme 2.

Synthesis of pseudodisaccharide **2**. All reactions involving arachidonoyl lipid were carried out with exclusion of light and air. Reagents and conditions: a) stearic acid, EDCI, DMAP, CH_2Cl_2 -DMF (4:1), 70%; b) AcOH, CH_2Cl_2 , H_2O , 69%; c) TBSCl, imidazole, DMF, 77%; d) arachidonic acid, EDCI, DMAP, CH_2Cl_2 -DMF (9:1), 99%; e) $\text{Et}_3\text{N}\cdot 3\text{HF}$, THF, CH_3CN , 98%; f) diisopropylammonium tetrazolide, CH_2Cl_2 , CH_3CN , 88%; g) **5**, 1*H*-tetrazole, CH_2Cl_2 ; then *t*-BuOOH, -40°C ; h) $\text{Et}_3\text{N}\cdot 3\text{HF}$, THF, CH_3CN , 55% (two steps). DMAP = 4-dimethylamino pyridine, DMF = *N,N*-dimethylformamide, EDCI = 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, TBS = *tert*-butyldimethylsilyl.

Scheme 3.

Synthesis of mannosyl donors **8** and **9**. a) NaOMe, MeOH; b) TBDPSCl, imidazole, DMF, 68% (two steps); c) NaH, PMBCl, DMF, 71%; d) AcOH, CH₂Cl₂, H₂O, 78%; e) Cl₃CCN, DBU, CH₂Cl₂, 94%; f) NaH, PMBCl, DMF, 85% (two steps); g) PdCl₂, NaOAc, AcOH, H₂O, 70%; h) Cl₃CCN, DBU, CH₂Cl₂, 92%. DBU = 1,8-diazabicycloundec-7-ene.

Synthesis of tetramannoside **24**. Reagents and conditions: a) **8**, TMSOTf (cat.), MS 4 Å, CH₂Cl₂, 72%; b) NaOMe, MeOH, CH₂Cl₂, 97%; c) **21**, TMSOTf (cat.), MS 4 Å, CH₂Cl₂, 44% (α only); d) NaOMe, MeOH, CH₂Cl₂, 78%; e) **9**, TMSOTf (cat.), MS 4 Å, CH₂Cl₂ (α : β = 3:2); f) Ti(Oi-Pr)₄, cyclopentylmagnesium chloride, THF, 78% (two steps); g) TESOTf, Et₃N, CH₂Cl₂, 76%. Tf = trifluoromethanesulfonyl, THF = tetrahydrofuran, TMS = trimethylsilyl.

Scheme 5.

Completion of GPI **1**. Reagents and conditions: a) NIS, AgOTf, TTBP, wet CH₂Cl₂, 92%; b) Cl₃CCN, DBU, CH₂Cl₂, 99%; c) **2**, TMSOTf (cat.), MS 4 Å, Et₂O; d) Et₃N·3HF, THF, CH₃CN, 39% (two steps); e) **4**, 1*H*-tetrazole, CH₂Cl₂, CH₃CN; then *t*-BuOOH, -40 °C, 37%; f) Zn, AcOH, CH₂Cl₂, 1 h; DBU, CH₂Cl₂, 1 h; CH₂Cl₂-TFA (9:1), 30 min, 90% (three steps). NIS = *N*-iodosuccinimide, TTBP = 2,4,6-tri-*tert*-butylpyrimidine.